# A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)

> **NCT04107961** · PHASE2 · WITHDRAWN · sponsor: **University of York**

## Conditions studied

- Post-kala-azar Dermal Leishmaniasis

## Interventions

- **BIOLOGICAL:** Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04107961
- **Lead sponsor:** University of York
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial will be undertaken but the protocol will be substantially revised.
- **Last updated:** 2022-09-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04107961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04107961, "A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04107961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*